PortfoliosLab logo
PFE vs. GSK
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between PFE and GSK is 0.41, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


-0.50.00.51.0
Correlation: 0.4

Performance

PFE vs. GSK - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Pfizer Inc. (PFE) and GlaxoSmithKline plc (GSK). The values are adjusted to include any dividend payments, if applicable.

20.00%40.00%60.00%80.00%100.00%NovemberDecember2025FebruaryMarchApril
65.06%
47.38%
PFE
GSK

Key characteristics

Sharpe Ratio

PFE:

-0.32

GSK:

-0.15

Sortino Ratio

PFE:

-0.30

GSK:

-0.02

Omega Ratio

PFE:

0.97

GSK:

1.00

Calmar Ratio

PFE:

-0.13

GSK:

-0.14

Martin Ratio

PFE:

-0.63

GSK:

-0.24

Ulcer Index

PFE:

12.38%

GSK:

16.08%

Daily Std Dev

PFE:

24.26%

GSK:

26.52%

Max Drawdown

PFE:

-58.96%

GSK:

-55.21%

Current Drawdown

PFE:

-56.70%

GSK:

-15.45%

Fundamentals

Market Cap

PFE:

$127.78B

GSK:

$75.01B

EPS

PFE:

$1.41

GSK:

$1.66

PE Ratio

PFE:

15.88

GSK:

22.31

PEG Ratio

PFE:

0.53

GSK:

0.35

PS Ratio

PFE:

2.01

GSK:

2.39

PB Ratio

PFE:

1.44

GSK:

4.10

Total Revenue (TTM)

PFE:

$48.75B

GSK:

$24.01B

Gross Profit (TTM)

PFE:

$31.22B

GSK:

$16.98B

EBITDA (TTM)

PFE:

$12.18B

GSK:

$5.14B

Returns By Period

In the year-to-date period, PFE achieves a -12.72% return, which is significantly lower than GSK's 12.10% return. Over the past 10 years, PFE has underperformed GSK with an annualized return of 0.39%, while GSK has yielded a comparatively higher 2.59% annualized return.


PFE

YTD

-12.72%

1M

-10.84%

6M

-17.89%

1Y

-7.85%

5Y*

-4.33%

10Y*

0.39%

GSK

YTD

12.10%

1M

-2.80%

6M

1.60%

1Y

-4.49%

5Y*

1.61%

10Y*

2.59%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

PFE vs. GSK — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PFE
The Risk-Adjusted Performance Rank of PFE is 3636
Overall Rank
The Sharpe Ratio Rank of PFE is 3535
Sharpe Ratio Rank
The Sortino Ratio Rank of PFE is 3030
Sortino Ratio Rank
The Omega Ratio Rank of PFE is 3030
Omega Ratio Rank
The Calmar Ratio Rank of PFE is 4444
Calmar Ratio Rank
The Martin Ratio Rank of PFE is 3939
Martin Ratio Rank

GSK
The Risk-Adjusted Performance Rank of GSK is 4242
Overall Rank
The Sharpe Ratio Rank of GSK is 4444
Sharpe Ratio Rank
The Sortino Ratio Rank of GSK is 3737
Sortino Ratio Rank
The Omega Ratio Rank of GSK is 3737
Omega Ratio Rank
The Calmar Ratio Rank of GSK is 4444
Calmar Ratio Rank
The Martin Ratio Rank of GSK is 4848
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

PFE vs. GSK - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Pfizer Inc. (PFE) and GlaxoSmithKline plc (GSK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The chart of Sharpe ratio for PFE, currently valued at -0.32, compared to the broader market-2.00-1.000.001.002.003.00
PFE: -0.32
GSK: -0.15
The chart of Sortino ratio for PFE, currently valued at -0.30, compared to the broader market-6.00-4.00-2.000.002.004.00
PFE: -0.30
GSK: -0.02
The chart of Omega ratio for PFE, currently valued at 0.97, compared to the broader market0.501.001.502.00
PFE: 0.97
GSK: 1.00
The chart of Calmar ratio for PFE, currently valued at -0.13, compared to the broader market0.001.002.003.004.005.00
PFE: -0.13
GSK: -0.14
The chart of Martin ratio for PFE, currently valued at -0.63, compared to the broader market-10.00-5.000.005.0010.0015.0020.00
PFE: -0.63
GSK: -0.24

The current PFE Sharpe Ratio is -0.32, which is lower than the GSK Sharpe Ratio of -0.15. The chart below compares the historical Sharpe Ratios of PFE and GSK, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-0.500.000.50NovemberDecember2025FebruaryMarchApril
-0.32
-0.15
PFE
GSK

Dividends

PFE vs. GSK - Dividend Comparison

PFE's dividend yield for the trailing twelve months is around 7.42%, more than GSK's 4.14% yield.


TTM20242023202220212020201920182017201620152014
PFE
Pfizer Inc.
7.42%6.33%5.70%3.12%2.64%3.92%3.68%3.12%3.54%3.70%3.48%3.34%
GSK
GlaxoSmithKline plc
4.14%4.60%3.75%4.78%4.92%5.49%4.28%5.55%5.72%7.06%5.96%6.09%

Drawdowns

PFE vs. GSK - Drawdown Comparison

The maximum PFE drawdown since its inception was -58.96%, which is greater than GSK's maximum drawdown of -55.21%. Use the drawdown chart below to compare losses from any high point for PFE and GSK. For additional features, visit the drawdowns tool.


-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%NovemberDecember2025FebruaryMarchApril
-56.70%
-15.45%
PFE
GSK

Volatility

PFE vs. GSK - Volatility Comparison

The current volatility for Pfizer Inc. (PFE) is 10.19%, while GlaxoSmithKline plc (GSK) has a volatility of 11.17%. This indicates that PFE experiences smaller price fluctuations and is considered to be less risky than GSK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


4.00%6.00%8.00%10.00%12.00%NovemberDecember2025FebruaryMarchApril
10.19%
11.17%
PFE
GSK

Financials

PFE vs. GSK - Financials Comparison

This section allows you to compare key financial metrics between Pfizer Inc. and GlaxoSmithKline plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items